Response to pancuronium after loss of atracurium-induced neuromuscular blockade.
OBJECTIVE
To describe a previously unreported event in which a patient became refractory to atracurium-induced neuromuscular blockade, but subsequently was adequately paralyzed with a standard dosage of pancuronium.


METHODS
A previously healthy 17-year-old woman who sustained multiple trauma developed tolerance to an atracurium infusion she was receiving while undergoing mechanical ventilation. On day 3 of neuromuscular blockade, she became unresponsive to atracurium as evidenced by excessive physical movement, increased peak airway pressures, and overbreathing assist control ventilation. Repeat boluses and increases in the atracurium infusion rate to a maximum of 1.27 mg/kg/h failed to provide a desired clinical response. A bolus dose of pancuronium 0.15 mg/kg was administered and the constant infusion was then changed to pancuronium 0.078 mg/kg/h. Within minutes, decreased respirations, peak airway pressures, and agitation were noted. The pancuronium infusion rate was then tapered to 0.045 mg/kg/h over 72 hours and continued to maintain adequate neuromuscular blockade.


CONCLUSIONS
Potential pharmacokinetic and pharmacodynamic causes of loss of neuromuscular blockade in this patient are postulated. Possible explanations for loss of neuromuscular blockade include increased degradation of atracurium and/or a change in acetylcholine receptor physiology.


CONCLUSIONS
The development of resistance to a specific neuromuscular blocking agent in the intensive care setting does not necessarily imply cross-tolerance or resistance to alternative agents. Also, loss of respiratory control by one neuromuscular blocking agent may be overcome by changing agents.
Kelly
K J
KJ
College of Pharmacy, University of Minnesota, Minneapolis.
Clarens
D M
DM
Kohls
P R
PR
Nahum
A
A
Vance-Bryan
K
K
D000293:Adolescent; D001279:Atracurium / Q000008:administration & dosage / Q000494:pharmacology*; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D009469:Neuromuscular Junction / Q000187:drug effects*; D010197:Pancuronium / Q000494:pharmacology*
D001279:Atracurium; D010197:Pancuronium